
    
      United Kingdom-only prospective, non-interventional, investigator-led, multi-centre, single
      cohort, registry. The observation period for each patient covers the treatment period with
      rivaroxaban and follow up until study end. For each patient, the treating health care
      professional records patient demographics, medical history, signs and symptoms, diagnosis,
      treatment and safety parameters at an initial visit and subsequent follow-up visit(s). Data
      monitoring will be undertaken by the Sponsor.
    
  